Results 181 to 190 of about 192,309 (409)

Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation.

open access: yesJournal of Managed Care & Specialty Pharmacy, 2017
BACKGROUND The use of non-vitamin K oral anticoagulants (NOACs) has increased steadily following marketing approval; however, their relative safety in nonvalvular atrial fibrillation (NVAF) patients in real-world clinical practice remains unclear ...
G. Adeboyeje   +7 more
semanticscholar   +1 more source

Design, synthesis, and characterization of polymer‐hydrogel composite vascular grafts using double‐expanded polytetrafluoroethylene to achieve enhanced mechanical and biological properties

open access: yesPolymer Engineering &Science, EarlyView.
A layer of bioactive P(AAm‐co‐NaAMPS)‐xanthan‐alginate hydrogel was introduced onto the inner surface of double‐expanded PTFE (dePTFE) vascular grafts to create synergy that results from the mechanical support and biomimetic properties of dePTFE vascular grafts and the enhanced cytocompatibility, endothelialization, and burst pressure resistance of the
Zhutong Li   +3 more
wiley   +1 more source

Alternative therapy interaction with warfarin: what doctors should know

open access: yesКардиоваскулярная терапия и профилактика, 2010
Warfarin effectiveness and safety is substantially affected by concurrent therapy. This paper reviews the main mechanisms of warfarin interactions with other agents, which underlie adverse effect development: platelet dysfunction, gastro-intestinal ...
T. B. Kozlova   +3 more
doaj  

Graves’ Disease and Treatment Effects on Warfarin Anticoagulation

open access: yesCase Reports in Medicine, 2014
Background. Hyperthyroidism causes an increased hypoprothrombinemic response to warfarin anticoagulation. Previous studies have demonstrated that patients with hyperthyroidism require lower dosages of warfarin to achieve a therapeutic effect.
Amanda Howard-Thompson   +4 more
doaj   +1 more source

Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice

open access: yesThrombosis and Haemostasis, 2017
Summary The ARISTOTLE trial showed a risk reduction of stroke/systemic embolism (SE) and major bleeding in non-valvular atrial fibrillation (NVAF) patients treated with apixaban compared to warfarin.
Xiaoyan Li   +11 more
semanticscholar   +1 more source

Ten‐year follow‐up of a case of eosinophilic granulomatous with polyangiitis

open access: yes
ESC Heart Failure, EarlyView.
Jiange Qiao   +6 more
wiley   +1 more source

New polymorphisms of Vkork1 gene related to anticoagulant resistance of rats and mice in Italy

open access: yesPest Management Science, EarlyView.
This study firstly reports on Vkorc1 gene mutations associated to anticoagulant rodenticide (AR) resistance in rats from Italy, and in rodents from Emilia‐Romagna region. New mutations probably involved in resistance have been described and the impact of these on rodenticide resistance was then studied via molecular docking with AR.
Alessandro Reggiani   +10 more
wiley   +1 more source

Warfarin Resistance: A Case Report

open access: yesEurasian Journal of Emergency Medicine, 2019
Warfarin is the most widely prescribed anticoagulant in the world. Patients who need more than 15 mg per day should be considered warfarin-resistant.
Uğur Gönlügür   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy